- Home
- REPL vs RGR Comparison
REPL vs RGR Comparison
Compare REPL & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- RGR
- Stock Information
- Founded
- REPL 2015
- RGR 1949
- Country
- REPL United States
- RGR United States
- Employees
- REPL N/A
- RGR N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- RGR Ordnance And Accessories
- Sector
- REPL Health Care
- RGR Industrials
- Exchange
- REPL Nasdaq
- RGR Nasdaq
- Market Cap
- REPL 547.0M
- RGR 616.8M
- IPO Year
- REPL 2018
- RGR N/A
- Fundamental
- Price
- REPL $5.56
- RGR $34.24
- Analyst Decision
- REPL Buy
- RGR
- Analyst Count
- REPL 10
- RGR 0
- Target Price
- REPL $8.25
- RGR N/A
- AVG Volume (30 Days)
- REPL 24.2M
- RGR 221.8K
- Earning Date
- REPL 08-07-2025
- RGR 07-30-2025
- Dividend Yield
- REPL N/A
- RGR 2.04%
- EPS Growth
- REPL N/A
- RGR N/A
- EPS
- REPL N/A
- RGR 0.35
- Revenue
- REPL N/A
- RGR $536,291,000.00
- Revenue This Year
- REPL N/A
- RGR N/A
- Revenue Next Year
- REPL $194.05
- RGR $2.58
- P/E Ratio
- REPL N/A
- RGR $98.98
- Revenue Growth
- REPL N/A
- RGR 3.31
- 52 Week Low
- REPL $2.68
- RGR $31.64
- 52 Week High
- REPL $17.00
- RGR $42.76
- Technical
- Relative Strength Index (RSI)
- REPL 44.05
- RGR 47.80
- Support Level
- REPL $4.49
- RGR $32.84
- Resistance Level
- REPL $6.39
- RGR $34.91
- Average True Range (ATR)
- REPL 0.77
- RGR 0.96
- MACD
- REPL 0.09
- RGR 0.17
- Stochastic Oscillator
- REPL 48.77
- RGR 71.43
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About RGR Sturm Ruger & Company Inc.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.